Jove
Visualize
Contact Us

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

24.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
24.7K
Alternative RNA Splicing02:18

Alternative RNA Splicing

5.0K
5.0K
RNA Splicing01:32

RNA Splicing

60.4K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.4K
Chromatin Structure and RNA Splicing02:41

Chromatin Structure and RNA Splicing

3.4K
3.4K
Lung Capacity01:47

Lung Capacity

56.2K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Null and Alternative Hypotheses01:16

Null and Alternative Hypotheses

12.5K
The actual hypothesis testing begins by considering two hypotheses. They are termed  the null hypothesis and the alternative hypothesis. These hypotheses contain opposing viewpoints.
The null hypothesis, denoted by H0 is a statement of no difference between the variables—they are not related. This can often be considered the status quo. As  a result if you cannot accept the null, it requires some action.
The alternative hypothesis, denoted by H1 or Ha, is a claim about the...
12.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.

British journal of cancer·2026
Same author

Sociodemographic inequalities in non-small cell lung cancer (NSCLC) novel treatments: a national population-based cohort study.

Journal of epidemiology and community health·2026
Same author

Comprehensive Profiling Reveals Sialyl-Tn Upregulation and Prognostic Value in Prostate Cancer.

Pathology international·2026
Same author

The glycobiology of prostate cancer: an update.

Oncogene·2026
Same author

Comprehensive profiling reveals Sialyl-Tn upregulation and prognostic value in prostate cancer.

bioRxiv : the preprint server for biology·2026
Same author

Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms.

Lung cancer (Amsterdam, Netherlands)·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 24, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.3K

Alternative splicing in lung cancer.

Alice O Coomer1, Fiona Black2, Alastair Greystoke3

  • 1Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, United Kingdom of Great Britain and Northern Ireland.

Biochimica Et Biophysica Acta. Gene Regulatory Mechanisms
|June 2, 2019
PubMed
Summary

Aberrant alternative splicing in lung cancer affects cell functions and prognosis. Understanding these splicing changes and altered splicing factors offers new therapeutic targets for this deadly disease.

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data
08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.4K

Related Experiment Videos

Last Updated: Jan 24, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.3K
Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.4K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data
08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer exhibits high mortality and heterogeneity, often diagnosed at late stages.
  • Aberrant alternative splicing significantly impacts cell functions, including apoptosis and proliferation in lung cancer.
  • Specific genes like BCL2L1, MDM2, MDM4, NUMB, and MET are implicated in lung tumourigenesis through altered splicing.

Purpose of the Study:

  • To investigate the role of aberrant alternative splicing in lung cancer development.
  • To identify key splicing factors and their altered expression in lung cancer.
  • To explore the potential of targeting splicing events for improved lung cancer treatment.

Main Methods:

  • Analysis of RNA sequencing datasets to identify aberrant splicing events.
  • Examination of expression levels of splicing factors in lung cancer tissues.
  • Review of literature on known aberrantly spliced genes and regulatory splicing factors.

Main Results:

  • Global RNASeq analyses suggest numerous influential aberrant splicing events in lung cancer.
  • Altered expression of splicing factors such as QKI, RBM4, RBM5, RBM6, RBM10, and SRSF1 is observed.
  • These factors regulate frequently referenced aberrant splicing events critical to lung cancer progression.

Conclusions:

  • Aberrantly spliced genes and altered splicing factors provide insights into lung cancer pathogenesis.
  • Understanding these molecular changes opens avenues for novel therapeutic strategies.
  • Targeting RNA structure and splicing regulation holds promise for future lung cancer therapies.